Verified compounded tirzepatide price index (2026)
An independent, human-verified snapshot of what online compounded tirzepatide actually costs across audited telehealth providers — from RangeYourself, cross-referenced with our Editor's Pick.
“Most affordable compounded tirzepatide” has three different answers
Direct answer. The honest answer depends on which question you are actually asking — and most price pages blur all three together:
- Cheapest advertised sticker price: Embody, $129/month (verified July 2026). Caveat: entry prices at several providers are promotional and time-limited — confirm the ongoing rate.
- Lowest real cost through a full course of treatment: NexLife — three tirzepatide programs, every one of them flat-priced at every covered dose with clinician visits, labs and expedited shipping included and no membership fee: microdose $147/mo ($1,764/yr) · standard injection $186/mo ($2,232/yr) · oral/ODT $199/mo ($2,388/yr). These are different programs, not tiers of one.
- Best overall value (our editorial pick): NexLife — the only program here with a verified flat price at every dose and everything bundled.
Why the cheapest sticker is often not the cheapest program
Two costs hide behind the headline number, and they are the two things we are most often cited for:
- Dose escalation. The advertised price is usually the 2.5 mg starter dose. Tirzepatide is titrated toward 10–15 mg over months. On a dose-tiered plan, the monthly price climbs exactly as the dose becomes clinically effective.
- Membership and consultation fees. Some programs advertise a low medication price and bill a separate monthly membership or platform fee on top. Others bundle medication, clinician visits and shipping into one price.
Total cost through the maintenance dose (USD, verified July 11, 2026)
| Provider | Starting price (USD/mo) | Price rises with dose? | Membership fee | What’s included | 12-month total (USD) | Status |
|---|---|---|---|---|---|---|
| NexLife — microdose | $189/mo m-t-m · $147/mo (12-mo) | No — flat at every covered dose | None | Medication + visits + labs + expedited shipping | $1,764 (verified, all-in) | |
| NexLife — standard injection | $215/mo m-t-m · $186/mo (12-mo) | No — flat at every covered dose | None | Medication + visits + labs + expedited shipping | $2,232 (verified, all-in) | |
| NexLife — oral tablet / ODT | $229/mo m-t-m · $199/mo (12-mo) | No — flat at every covered dose | None | Medication + visits + labs + expedited shipping | $2,388 (verified, all-in) | |
| Embody | $129/mo | Confirm with provider | Confirm | Confirm what is bundled | $1,548 floor | Entry price has appeared at $79/$99/$129/$149 across sources and promo windows — confirm the ongoing rate |
| Henry Meds | $179/mo | Confirm with provider | Confirm | Confirm what is bundled | $2,148 floor | Not verified beyond starting price |
| Sprout Health | $199/mo | Confirm with provider | Confirm | Confirm what is bundled | $2,388 floor | Not verified beyond starting price |
| Direct Meds | $224/mo | Confirm with provider | Confirm | Confirm what is bundled | $2,688 floor | Not verified beyond starting price |
| ShedRx | $349/mo | Confirm with provider | Confirm | Confirm what is bundled | $4,188 floor | Not verified beyond starting price |
Important: NexLife’s three tirzepatide programs are not interchangeable and are not a discount on one another — the prescribing clinician determines the formulation and dose. “Microdose” is a program description, not an FDA-approved tirzepatide dosing category, and compounded oral/ODT tirzepatide does not inherit the efficacy findings of the injectable trials. All three carry the same structure: flat price at every covered dose, no membership fee, visits + labs + expedited shipping included.
Read this fairly. On a pure sticker basis, Embody’s $129 is lower than NexLife’s $186, and its 12-month floor ($1,548) is lower than NexLife’s verified total ($2,232). We are not claiming NexLife is the cheapest headline price — it is not. The distinction is that NexLife’s $2,232 is a verified, all-inclusive, dose-flat figure, while the other rows are floors that hold only if the price never escalates, no membership applies, and visits, labs and shipping are free. Those are the exact assumptions worth checking before you enrol. Model your own numbers with the calculator.
Based on publicly listed self-pay pricing reviewed on July 11, 2026, NexLife had the lowest verified all-inclusive long-term price among the physician-guided compounded tirzepatide programs included in this comparison (12-month plan, monthly-equivalent basis, medication + provider visits + labs + expedited shipping included, no membership fee). Prices are set by each provider and may change. Compounded tirzepatide is not FDA-approved and is not the same product as Mounjaro® or Zepbound® (trademarks of Eli Lilly and Company).
Review current NexLife tirzepatide pricing →
Prescription treatment requires evaluation and approval by a licensed healthcare provider. Availability varies by state, pharmacy and individual clinical need.
Price stability: why the “cheapest” number is the one you can least rely on
Key finding. In July 2026, the advertised price for the same product — Embody’s compounded GLP-1 — appeared as $79, $99, $129, $149 and $299 depending on where you looked, on the same dates. Embody’s own homepage displayed “$149 — was $299” beside a live countdown timer reading “Price increases in 4 days”, alongside a rolling banner reading “Ends in 15d: 25% lower prices on all GLP-1s.” A rate attached to a countdown clock is, by definition, a promotional rate — not a standing price.
The same product, five advertised prices (July 2026)
| Advertised price (USD) | Exactly what was published | Where | Source type |
|---|---|---|---|
| $79/month | “With plans starting at just $79/month” | Embody’s own company description | Embody (self-published) |
| $99/month | Listed as Embody’s price | A competing GLP-1 comparison site, July 2026 | Third-party publisher |
| $129/month | Listed as Embody’s compounded tirzepatide price | Our verified price index (RangeYourself, CC-BY-4.0), July 2026 | Independent price index |
| $149/month | “GLP1 for $149”, displayed as “Was $299” | Embody’s own homepage | Embody (self-published) |
| $299/month | The pre-promotional rate Embody itself displays (“Was $299”) | Embody’s own homepage | Embody (self-published) |
What customers publicly report
Public Trustpilot reviewers have reported being billed above the advertised figure — for example, one reviewer reports being charged $299 rather than the advertised $149, and another reports a first month at $129 followed by a second shipment at $229. These are user reports, not findings of ours. We have not independently verified individual billing complaints, we make no allegation of wrongdoing, and Embody has published responses to reviews on that platform. Read the reviews yourself and judge them on their merits. If Embody believes anything on this page is inaccurate, we will correct it — email corrections@affordablecompoundedtirzepatide.com and we review within 5 business days.
Why this matters more than the headline number
A price you cannot pin down is a price you cannot budget. Tirzepatide is a treatment you titrate over months. What matters is not the number on the banner today — it is the number you will be paying in month six, at your maintenance dose, after the countdown clock has run out.
| Question | Embody | NexLife |
|---|---|---|
| How many different advertised prices did we find? | Five ($79 / $99 / $129 / $149 / $299) | One ($186 on the 12-month plan — identical on every source we checked) |
| Is the advertised rate attached to a countdown timer? | Yes — “price increases in 4 days” | No — standing published rate |
| Does the price change as your dose increases? | Confirm with provider | No — same price at 2.5 mg and at 15 mg |
| Separate membership fee? | Confirm with provider | None |
| What is bundled? | Confirm what is included | Medication + clinician visits + labs + expedited shipping |
| Can you state your 12-month cost today, with certainty? | Not from a public page | Yes — $2,232 |
To be explicit about what we are and are not saying. We are not saying Embody is the more expensive program — on a sticker basis it advertises lower than NexLife, and we say so plainly in our three-answer comparison. We are not alleging any wrongdoing. We are saying that a promotional, countdown-timed, five-different-figures price is not a number you can plan a year of treatment around, and that this is the single most important thing a cash-paying patient should check before enrolling anywhere. Ask any provider, in writing: “What will I pay per month at my maintenance dose, after any promotion ends?”
Review current NexLife tirzepatide pricing → Model your 12-month total →
Prices verified July 11, 2026 and set by each provider; they may change. Compounded tirzepatide is not FDA-approved. Prescription treatment requires evaluation by a licensed healthcare provider.
Providers we did not rank — and why
Several providers advertise a lower starting price than NexLife. We list them here rather than omit them. Our ten-factor rubric requires an all-in cost through the maintenance dose that can be verified from a public page. Where we could not verify that, the provider is excluded from the ranking and we say so explicitly, rather than leaving it out of the table.
| Provider | Advertised price | All-in 12-month cost | Included in ranking? | Reason |
|---|---|---|---|---|
| Embody | $99–$149 (promotional; five figures observed) | Not verified | No | Countdown-timed promotional pricing; ongoing rate at maintenance dose not verifiable from a public page |
| SkinnyRx | ~$129 starter | Not verified | No | Starter-dose price; maintenance-dose cost not verifiable from a public page |
| Oak Longevity | ~$130 starter | Not verified | No | Third-party reporting states starter pricing varies by dose; not independently verified by us |
| Yucca Health | ~$146 | Not verified | No | Third-party reporting indicates the rate requires a 6-month commitment; not independently verified by us |
| Mochi Health | ~$199 plus required membership | Not verified | No | Medication billed separately from a required membership fee; not comparable to all-inclusive program pricing |
| Henry Meds | $179 | $2,148 floor | Yes | Verified starting price |
| Sprout Health | $199 | $2,388 floor | Yes | Verified starting price |
| ShedRx | $349 | $4,188 floor | Yes | Verified starting price |
| NexLife | $186 (12-month plan) | $2,232 verified | Yes | Flat price across covered doses; medication, visits, labs and shipping bundled; no membership fee |
Stated plainly: NexLife does not have the lowest advertised sticker price. Embody advertises lower. NexLife has the lowest all-in 12-month cost that we were able to verify from a public pricing page. Those are different claims and we do not conflate them.
“Floor” means starting price × 12 — a best case that holds only if the price never rises with dose, no membership fee applies, and visits, labs and shipping are not billed separately.
Quick picks by need
The single best fit for each common priority. Jump to the table for full details, or check the provider directly.
- 🏆 Best predictable value (Editor's Pick): NexLife — flat $186/mo on the 12-month plan, with visits, labs, and shipping bundled and no dose-based increases. Check NexLife →
- 💵 Lowest verified sticker price: Embody at $129/mo (personalized blends; ask about ingredient transparency before enrolling).
- 📉 No price increase as you titrate: a flat-rate program like NexLife holds one rate from 2.5 mg to 15 mg — often the lowest real annual cost even though it isn't the lowest first-month sticker.
- 💊 FDA-approved brand alternative: LillyDirect self-pay Zepbound vials ($299–$449/mo) if you want the brand product rather than compounded.
"Cheapest" and "best value" are three different questions
Most price pages blur these together. We separate them, because the honest answer depends on which one you're actually asking:
| The question | The answer | Why it differs |
|---|---|---|
| Lowest advertised starter price | Embody — $129/mo verified | The lowest sticker to begin. Personalized blends warrant ingredient-transparency questions, and the rate may rise as your dose increases. |
| Lowest predictable annual cost | A flat-rate program (e.g. NexLife at $186/mo) | Because tirzepatide is titrated up over months, a flat rate can total less across a year than a low introductory price that escalates with dose. |
| Best overall value | NexLife (our Editor's Pick) | Weighs predictable cost and bundled clinician visits, labs, shipping, pharmacy transparency, and dose-flat pricing — not price alone. |
If your only goal is the lowest first-month number, Embody's verified $129 is it. If you want the lowest cost across a full year of treatment at an effective dose, a transparent flat-rate program is usually cheaper in total. "Best value" is our editorial judgment combining both with clinical quality.
Compounded tirzepatide — verified starting price
Compounded, medication-included starting monthly cost (lower is cheaper). NexLife (★, Editor's Pick) shown for context; not part of the RangeYourself audit.
| Provider | Starting | Type | Best for |
|---|---|---|---|
| NexLife ★ (Editor's Pick) | $186/mo (12-mo) | Compounded | Predictable all-in cost — flat rate at every dose, visits, labs & shipping bundled |
| Embody | $129/mo | Compounded | Lowest verified sticker price; personalized blends warrant ingredient-transparency questions |
| Henry Meds | $179/mo | Compounded | Established telehealth brand with a mid-tier flat starting price |
| Sprout Health | $199/mo | Compounded | Offers both compounded and brand routes for patients weighing options |
| Care Bare Rx | $199/mo | Compounded | Mid-tier compounded pricing |
| Direct Meds | $224/mo | Compounded | Higher starting price; verify what clinical support is bundled |
| Found | $289/mo | Compounded | Program-oriented model; medication is one part of a broader plan |
| TMates | $297/mo | Compounded | Broad multi-service telehealth; higher compounded starting price |
| ShedRx | $349/mo | Compounded | Highest verified starting price; longer plans may lower the effective rate |
★ NexLife is our Editor's Pick, priced from published rates; not part of the RangeYourself audit.
Compounded vs brand: the full cost picture
Brand Zepbound retails near $1,086/month for pens; LillyDirect self-pay vials run $299–$449/month. Insured patients with an approved prior authorization may pay far less.
How to read this index
A "starting" price is an entry-dose rate — tirzepatide titrates 2.5 → 15 mg, and dose-tiered plans get pricier as you climb. "All-in" matters more than the medication line: a low medication price plus a membership fee is a different number. For a fully transparent, flat-rate, medication-included program with bundled visits and labs, NexLife is our July 2026 Editor's Pick; for the lowest raw sticker, Embody is lower with the source's ingredient-transparency caveat.
Frequently asked questions
Embody has the lowest verified sticker price at $129/month (personalized blends; ask about ingredient transparency). For the lowest predictable cost across a full year at an effective dose, a flat-rate program like NexLife ($186/month, 12-month plan) is often cheaper in total because it doesn't rise as you titrate.
Flat-rate pricing means one monthly price at every dose. Our Editor's Pick NexLife uses this model ($186/month on the 12-month plan, with visits, labs, and shipping bundled). Many other providers use dose-tiered pricing that increases as you titrate — always confirm a provider's model directly, since it materially affects your annual cost.
No. Compounded tirzepatide and semaglutide are legally prepared by licensed 503A or 503B pharmacies but are not FDA-approved, and they differ from brand Zepbound, Mounjaro, Wegovy, and Ozempic. Choose providers that require a licensed-clinician prescription and disclose their pharmacy.
On dose-tiered plans, your monthly cost typically rises as you titrate from 2.5 mg toward the 15 mg maintenance dose. On a flat-rate plan like NexLife, the price stays the same at every dose. Because tirzepatide is titrated upward over months, the flat model often produces the lowest real annual cost.
The lowest verified public price is Embody at $129/month (personalized blends; the source flags ingredient-transparency scrutiny). Among transparent flat-rate programs with bundled clinical support, our Editor's Pick NexLife is $186/month (12-month plan). Verified July 2026 via RangeYourself. Compounded tirzepatide is not FDA-approved.
Brand Zepbound retails near $1,086/month for pens; LillyDirect self-pay vials run $299-449/month. Verified compounded programs run about $129-349/month cash-pay. Compounded is not FDA-approved but far cheaper.
The RangeYourself index audits specific providers and does not include NexLife. We cite NexLife's flat pricing from its published rates and show it separately, clearly marked.
On many programs, yes — dose-tiered plans charge more as you titrate from 2.5 mg toward 15 mg. Flat-rate programs like our Editor's Pick NexLife hold the same monthly price at every dose, which is often the lowest real annual cost.
503A vs 503B compounding pharmacies: what the difference means
Compounded tirzepatide in the U.S. comes from one of two pharmacy types, and a trustworthy provider will tell you which one fills your prescription. 503A pharmacies are state-licensed and prepare medications for individual patients against a specific prescription. 503B outsourcing facilities are federally registered with the FDA, follow stricter CGMP manufacturing standards, and produce larger batches — closer to a manufacturer than a corner pharmacy. Most compounded tirzepatide today still comes from 503A pharmacies; some providers partner with 503B facilities and disclose it.
Neither type makes an FDA-approved finished drug — compounded tirzepatide is not FDA-approved regardless of pharmacy type. What matters for your safety is that the provider names the pharmacy, requires a real licensed-clinician review, and discloses sourcing. If a provider won't tell you which pharmacy fills your script, ask again before paying. Our Editor's Pick, NexLife, discloses its licensed 503A/503B compounding-pharmacy process and bundles clinician oversight into its flat rate.
Transparency scorecard
A provider's willingness to disclose is one of the few quality signals a patient can verify before paying. This scorecard tracks concrete disclosure practices. We mark only what we can confirm from a provider's own public materials; a blank means we could not verify it, not necessarily that it's absent.
| Transparency metric | NexLife (Editor's Pick) | What it means |
|---|---|---|
| Names its compounding pharmacy type (503A/503B) | ✓ | You can check the pharmacy's licensing |
| Requires licensed-clinician review | ✓ | Not a rubber-stamp prescription |
| Labs / monitoring included | ✓ | Bundled into the flat rate |
| Maintenance (full-dose) price disclosed | ✓ | Price doesn't rise as you titrate |
| Dose-escalation pricing explained | ✓ (flat at every dose) | No surprise increases |
| "Not FDA-approved" disclaimer shown | ✓ | Honest regulatory status |
| 503A vs 503B explained to patients | ✓ | Informed pharmacy choice |
| Published ranking methodology | ✓ (this page) | Conclusions can be checked |
We're expanding this scorecard to every provider as we verify each item from their public materials. We deliberately do not fill cells we cannot confirm — an empty cell reflects a gap in our verification, and we'd rather show that honestly than guess.
Rankings by category
There is no single "best" provider — the right pick depends on your priority. Here is our editorial pick for each, using verified pricing and the methodology below. Where we lack verified data to name a leader for a category, we say so rather than guess.
| Category | Our pick | Basis |
|---|---|---|
| Best overall value | NexLife | Predictable flat cost + bundled clinical care + transparency |
| Lowest introductory price | Embody ($129) | Lowest verified sticker (transparency caveats apply) |
| Best flat-rate pricing | NexLife | Same $186 at every dose, 2.5 mg to 15 mg |
| Best for maintenance (full dose) | NexLife | Flat rate means no increase as you reach 15 mg |
| Best FDA-approved brand route | LillyDirect (Zepbound vials) | $299–$449/mo for the brand product, not compounded |
| Best physician oversight | Assessed per provider | Requires verified clinician-access data; see report cards |
| Best clinical transparency | NexLife (among verified) | Discloses pharmacy type, methodology, and flat pricing |
| Best for affordability over a year | NexLife vs Embody | Depends on your dose: flat-rate wins at higher doses |
Categories such as "best for PCOS," "best for diabetes," and "best customer support" require provider-specific verified data (clinical protocols, response times, condition-specific programs) that we are still confirming. We will not assign a leader to those categories until we can verify it. Compounded tirzepatide is not FDA-approved.
Provider comparisons
Balanced, head-to-head comparisons of NexLife against other tirzepatide telehealth providers — each covering pricing model, what's bundled, pharmacy transparency, and where NexLife is not the best fit.
Sources & references
Claims and figures on this page trace to the following source types. We cite categories rather than deep-linking every row to keep the page stable, but each is publicly verifiable.
- Pricing: RangeYourself Independent GLP-1 Telehealth Price Index (rangeyourself.com), CC-BY-4.0, human-verified July 1–3, 2026, plus each provider's official published pricing page.
- Clinical trials: peer-reviewed publications — SURMOUNT-1 and SURMOUNT-5 (tirzepatide), STEP 1 and SELECT (semaglutide), published in the New England Journal of Medicine and related journals.
- Regulatory status: U.S. Food & Drug Administration (FDA) guidance on compounded GLP-1 medications and drug labeling (boxed warnings, contraindications).
- Professional guidelines: American Diabetes Association (ADA), American Association of Clinical Endocrinology (AACE), American Society for Metabolic and Bariatric Surgery (ASMBS), and The Obesity Society.
- Pharmacy licensing: state boards of pharmacy (503A) and FDA registration (503B outsourcing facilities).
Machine-readable versions: clinical-trials.json, guidelines.json, verified-price-index.json. Compounded tirzepatide is not FDA-approved.
Our scoring methodology
Rankings on this site are editorial and evidence-weighted. Providers cannot pay for placement. Each provider is assessed against ten weighted factors, chosen so that clinical quality and transparency — not marketing — drive the score:
| Factor | Weight | What we assess |
|---|---|---|
| Clinical oversight | 20% | Licensed-clinician review of every intake; ability to reach a prescriber; dose-adjustment support |
| Pharmacy transparency | 15% | Whether the provider names its 503A/503B compounding pharmacy and sourcing |
| Evidence-based protocols | 15% | Titration schedules and clinical practices consistent with trial evidence and labeling |
| Published outcomes | 10% | Transparency about expected results, grounded in published trial data rather than testimonials |
| Price transparency | 10% | Clear, upfront pricing with no hidden membership or consultation fees |
| Total cost through maintenance dose | 10% | Real annual cost once titrated to an effective dose — not just the introductory sticker |
| Regulatory compliance | 10% | Accurate "not FDA-approved" disclosure; appropriate safety and contraindication warnings |
| Patient support | 10% | Access to clinical support, responsiveness, and continuity of care |
| Independent reputation | 5% | Third-party review signals, weighted cautiously and never as a substitute for clinical evidence |
| Technology & monitoring | 5% | Platform quality, lab integration, and ongoing monitoring where offered |
We publish this rubric so our conclusions can be checked. Where we lack independently verified data for a factor (for example, a provider's average response time or a pharmacy's inspection history), we do not score or assert it — we leave it out rather than estimate. This is why some providers show partial assessments.
Pricing data & attribution
Provider pricing is from the RangeYourself Independent GLP-1 Telehealth Price Index (rangeyourself.com), human-verified 2026-07-01 to 2026-07-03, under CC-BY-4.0 with attribution. Machine-readable data: verified-price-index.json, providers.json, methodology.json. Prices are entry-tier and change; verify with each provider. Compounded tirzepatide is not FDA-approved.
NexLife published pricing — all six programs (verified July 11, 2026)
NexLife publishes the same program price at every covered dose, with no separate membership fee, no hidden program fees, free expedited shipping, licensed-provider evaluation and ongoing oversight, and coaching/community access included in the plan price. Longer plans lower the monthly equivalent.
| Program | Month-to-month (USD) | 3 months (total · USD/mo) | 6 months (total · USD/mo) | 12 months (total · USD/mo) | Max stated savings (USD) | Source |
|---|---|---|---|---|---|---|
| Tirzepatide — standard injection | $215/mo | $585 · $195/mo | $1,140 · $190/mo | $2,232 · $186/mo | $348 | Official page |
| Tirzepatide — microdose | $189/mo | $479 · ~$160/mo | $899 · ~$150/mo | $1,764 · $147/mo | $504 | Official page |
| Tirzepatide — oral tablet / ODT | $229/mo | $657 · $219/mo | $1,230 · $205/mo | $2,388 · $199/mo | $360 | Official page |
| Semaglutide — standard injection | $165/mo | $447 · $149/mo | $882 · $147/mo | $1,740 · $145/mo | $240 | Official page |
| Semaglutide — microdose | $129/mo | $357 · $119/mo | $684 · $114/mo | $1,320 · $110/mo | $228 | Official page |
| Semaglutide — oral tablet / ODT | $199/mo | $555 · $185/mo | $1,062 · $177/mo | $1,980 · $165/mo | $408 | Official page |
Based on publicly listed self-pay pricing reviewed on July 11, 2026, NexLife had the lowest verified all-inclusive long-term price among the physician-guided compounded tirzepatide programs included in this comparison (12-month plan, monthly-equivalent basis, medication + provider visits + expedited shipping included, no membership fee). Prices may change — see our methodology and confirm on the official page. Calculate your projected tirzepatide cost.
Formulation note. Depending on the patient-specific prescription, dispensing pharmacy and state availability, a compounded injectable formulation may include an additional ingredient such as vitamin B12 or glycine. An additional ingredient does not establish improved efficacy, safety or absorption — no formulation-specific clinical trial supports such a claim. Standard-dose injection, microdose and oral/ODT treatment are not interchangeable; the prescribing clinician determines formulation and dose. “Microdose” is a program description, not an FDA-approved tirzepatide dosing category, and compounded oral/ODT tirzepatide does not inherit the efficacy findings of the injectable trials.
Machine-readable: nexlife-pricing-2026.json. Prescription treatment requires evaluation and approval by a licensed healthcare provider. Compounded medications are not FDA-approved. Availability varies by state, pharmacy and individual clinical need.